
Teva Pharmaceutical (TEVA) Stock Forecast & Price Target
Teva Pharmaceutical (TEVA) Analyst Ratings
Bulls say
Teva Pharmaceutical Indus is well positioned for growth, with recent acquisitions and a strong focus on developing innovative treatments, including a potential blockbuster drug for vitiligo and celiac disease. Analysts recommend overweighting the stock due to its strong pipeline and potential for significant sales growth. Additionally, Teva's recent earnings report showed strong performance and a focus on incremental innovation, which could lead to increased cash flow and strategic investments in the future.
Bears say
Teva Pharmaceutical Indus is facing headwinds in its pediatric Tourette portfolio acquisition, leading to slow script growth and delayed revenue recognition. The company's disciplined BD approach and focus on neuroscience and rare diseases could lead to future deals in the low-hundreds-of-millions range, but potential impairments of goodwill could impact financials in the coming quarters.
This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Teva Pharmaceutical (TEVA) Analyst Forecast & Price Prediction
Start investing in Teva Pharmaceutical (TEVA)
Order type
Buy in
Order amount
Est. shares
0 shares